List of Diagnostics Companies in Pennsylvania - 18

Aposcience AG aspires to improve the health of patients in need of regenerative medicine by commercially exploiting the therapeutic potential of secretomes derived from white blood cells (PBMCs) isolated from peripheral blood. PBMCs are currently a waste product of all blood transfusion units.

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Cerora (www.cerora.com) is devoted to alleviating suffering and empowering people by transforming antiquated opinion-based methods into enlightened biosensor-based neurodiagnostics. The company intends to make a major positive impact in brain health assessment globally with an initial focus on concussion. The Company is leading the way in the development and testing of mobile software and hardware technologies required to provide critical, objective, biomarker-based brain function diagnostic information. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania's Tech Ventures on Lehigh University's Mountaintop Campus in Bethlehem, Pennsylvania, Cerora has assembled a team of experienced medical scientists and management professionals.

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

InfraScan, Inc. is a medical device company that focuses on developing, commercializing, and distributing hand-held diagnostic devices for head injury and stroke assessment based on near infrared (NIR) technology. InfraScan Inc.'s patented NIR technology for diagnosing brain hematomas enables neurosurgeons to effectively, conveniently, and accurately detect intracranial bleeding in patients with Head Trauma.

The OcuCheck is a point-of-care device that uses a specialized electrical chemical sensor with proprietary coatings to measure specific biomarkers in the tear film Currently, the OcuCheck is the only device that can simultaneously measure MMP-9 and tear film osmolarity in one device. It is also one of the most accurate devices for quantitative measurement of MMP-9.

JBS Science is a biotechnology company that specializes in developing circulating cell-free DNA (cfDNA) in urine technology for improved cancer screening and management through liquid biopsy.

LifeLens was founded in 2014 by Dr. Robert Schwartz, Landy Toth, David Robins, and Dr. Robert Van Tassel. Its mission is to create simple, commercially viable technologies for high fidelity physiologic monitoring.

Lipella Pharmaceuticals, Inc. is a biotechnology company with a focus on supportive care to cancer survivors who acquire hemorrhagic cystitis. They are a clinical-stage pharmaceutical company with expertise in drug delivery and the treatment of urologic conditions.

OraSure Technologies developd, manufactured and distributed of point-of-care diagnostic tests, molecular collection devices. These include rapid tests for the detection of antibodies to HIV and Hepatitis C (HCV) on the OraQuick® platform; sample self-collection and stabilization products for molecular applications; and oral fluid laboratory tests for detecting various drugs of abuse. Orasure's wholly-owned subsidiaries include DNA Genotek, CoreBiome, and Novosanis.COVID-19: BARDA funded the development of a rapid coronavirus test that can be self-administered at home.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision's CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocor's precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.

Headquartered in Bethlehem, PA, Saladax Biomedical, Inc. is a privately held company that develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. Since 2007, Saladax's proprietary technology has been used in clinical laboratories or point-of-care settings to assist clinicians in monitoring and optimizing patient care. Additionally, the company collaborates with leading pharmaceutical companies to develop tests for clinical trials and companion diagnostics. For more information, visit MyCareTests.com.

Trice Medical™ was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payer by providing instant, eyes-on, answers. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians office. Our mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

Vibe Pharmaceuticals LLC is an early-stage drug discovery company, spun out of the University of Pennsylvania, developing effective therapeutics for musculoskeletal disorders which lead to bone and muscle loss. The Vibe Pharmaceuticals technology is based on the well-established scientific observation that mechanical stimulation of responsive tissues, including bone and muscle, leads to increases in bone density and muscle mass. The Company team has developed a drug discovery platform for molecules that mediate bone and muscle mass increases and has identified specific proteins, which are being studied as active therapeutic candidates for osteoporosis, sarcopenia and related indications.